Small Cell Lung Carcinoma

• 

  Subject Areas on Research

  • 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. 
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. 
  • A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. 
  • ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer. 
  • Advances in radiotherapy for tumors involving the mediastinum. 
  • Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. 
  • Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. 
  • Association between polymorphisms in the GSTA4 gene and risk of lung cancer: a case-control study in a Southeastern Chinese population. 
  • Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. 
  • Authors' Reply. 
  • Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). 
  • Commentary: Surgery for small cell lung cancer: This is the way. 
  • Commentary: Survival after small cell lung cancer resection: Small opportunity? 
  • Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. 
  • Do neuroendocrine cells come up large in small cell lung cancer? 
  • Effect of Lymph Node Assessment on Outcomes in Surgery for Limited Stage Small Cell Lung Cancer. 
  • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. 
  • Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. 
  • Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. 
  • Family matters: How MYC family oncogenes impact small cell lung cancer. 
  • Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. 
  • Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. 
  • Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. 
  • Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. 
  • Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. 
  • Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. 
  • Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. 
  • Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. 
  • Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. 
  • Killing SCLC: insights into how to target a shapeshifting tumor. 
  • Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. 
  • Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. 
  • MET and phosphorylated MET as potential biomarkers in lung cancer. 
  • MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. 
  • MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. 
  • MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. 
  • MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. 
  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. 
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. 
  • Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. 
  • Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. 
  • New Approaches to SCLC Therapy: From the Laboratory to the Clinic. 
  • Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. 
  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. 
  • Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. 
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). 
  • Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. 
  • Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). 
  • Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. 
  • Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. 
  • Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. 
  • Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. 
  • Reply to T.-H. Wang et al. 
  • Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
  • Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. 
  • Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. 
  • Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). 
  • Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Small cell bladder cancer: should we consider prophylactic cranial irradiation? 
  • Small cell lung cancer. 
  • Small cell lung cancer. 
  • Small-cell lung cancer: prognostic factors and changing treatment over 15 years. 
  • Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. 
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 
  • Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. 
  • Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-Stage Lung Cancer. 
  • TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. 
  • Tagging single nucleotide polymorphisms in MBD4 are associated with risk of lung cancer in a Chinese population. 
  • The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer. 
  • Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. 
  • Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. 
  • Tumor heterogeneity. 
• 

  Keywords of People

  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics